Large increase seen in number of lymph nodes evaluated for colon cancer

September 13, 2011

During the past two decades there has been a significant increase in the percentage of patients who have a high number of lymph nodes evaluated during colon cancer operations, but this improvement is not associated with an increase in the overall proportion of colon cancers that are node positive, according to a study in the September 14 issue of JAMA.

"As wide-ranging quality improvement efforts emerge throughout the , finding mechanisms for optimizing through accurate staging and appropriate treatment has become an area of substantial interest to policy makers. Among patients surgically treated for , several studies have demonstrated better survival for patients with more evaluated," according to background information in the article. "The proposed mechanism behind this association suggests that a more extensive lymph node evaluation reduces the risk of understaging, in which inadequate assessment may incorrectly identify a patient with node-positive disease as node negative, thus failing to identify appropriate treatment."

Most practice organizations and consensus panels now advocate for the surgical evaluation of 12 or more lymph nodes for acceptable staging of newly diagnosed colon cancer patients. "Recently, some studies have questioned the understaging mechanism, suggesting that efforts by payers and professional associations to increase the number of lymph nodes evaluated during colon cancer surgery may have a limited role in improving survival," the authors write.

Helen M. Parsons, M.P.H., of the National Cancer Institute, Bethesda, Md., and colleagues examined trends in the degree of lymph node evaluation for colon cancer and how they are associated with survival. The researchers analyzed data from the Surveillance, , and End Results (SEER) program, from 1988 through 2008. Included in the analysis were 86,394 patients surgically treated for colon cancer.

The researchers found that lymph node evaluation for colon cancer increased markedly from 1988 to 2008. During 1988-1990, 34.6 percent of patients (n = 3,875) received lymph node evaluation at a level of 12 lymph nodes or more. By 1994-1996, 37.9 percent of patients (n = 4,362) had an evaluation at this level, with this percentage increasing to 46.8 percent in 2000-2002 and 73.6 percent (9,798/13,310) in 2006-2008. Even though the number of lymph nodes evaluated increased significantly, this change was not associated with an increase in node-positive cancers over this period (40 percent in 1988-1990, 42 percent in 2006-2008).

The authors also found that although patients with high rates of lymph node evaluation were only slightly more likely to have node-positive disease, these patients experienced significantly lower relative hazard of 5-year death compared with those with fewer nodes evaluated. "When stratified by node positivity, patients with node-positive disease as well as node-negative disease continued to experience lower relative hazard of death when more lymph nodes were evaluated."

"In conclusion, the number of lymph nodes evaluated for colon cancer markedly increased in the past 2 decades but was not associated with an overall shift toward higher-staged cancers, questioning the upstaging mechanism as the primary basis for improved survival in patients with more lymph nodes evaluated."

More information: JAMA. 2011;306[10]:1089-1097.

Related Stories

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.